Richmond R L, Harris K, de Almeida Neto A
School of Community Medicine, University of New South Wales, Kensington.
Med J Aust. 1994 Jul 18;161(2):130-5. doi: 10.5694/j.1326-5377.1994.tb127344.x.
To evaluate the efficacy of the transdermal nicotine patch as an aid to smoking cessation when used as an adjunct to a cognitive-behavioural group intervention and to assess the effectiveness of the patch in ameliorating withdrawal symptoms.
Double-blind placebo-controlled randomised trial with six months' follow-up of those who returned to the hospital-based outpatients smoking cessation clinic.
Three hundred and thirteen smokers recruited from the local community. Mean age was 42 years, 48% were male, mean cigarette consumption was 29 per day and mean duration of smoking was 24 years.
Cognitive-behavioural intervention delivered in a group context, two hours once a week over five weeks, self-help manual, and 24-hour daily nicotine patch treatment for 10 weeks.
Point prevalence abstinence at three and six months, and sustained cessation from end of treatment to six months, with biochemical validation (expired carbon monoxide). We examined the effectiveness of the nicotine patch in ameliorating specific withdrawal symptoms by self-report of degree of severity.
The active nicotine patch resulted in significantly higher biochemically confirmed abstinence rates when compared with placebo at three months (48% v. 21%) and at six months (33% v. 14%). Six-months' continuous abstinence rates were also significantly higher among the active nicotine group (25%) compared with placebo (12%). The most common adverse events among active patch users were sleep disturbance and local skin irritation. The nicotine patch reduced the severity of some withdrawal symptoms. A low level of dependence was the strongest predictor of three and six months' abstinence.
The transdermal nicotine patch is effective when used as an adjunct to a group cognitive-behavioural intervention and it provides relief from withdrawal symptoms associated with nicotine dependence.
评估经皮尼古丁贴片作为认知行为团体干预辅助手段用于戒烟的疗效,并评估该贴片在缓解戒断症状方面的效果。
双盲安慰剂对照随机试验,对返回医院门诊戒烟诊所的患者进行为期六个月的随访。
从当地社区招募的313名吸烟者。平均年龄42岁,48%为男性,平均每日吸烟量29支,平均吸烟时长24年。
团体形式的认知行为干预,为期五周,每周一次,每次两小时,提供自助手册,以及为期10周的每日24小时尼古丁贴片治疗。
三个月和六个月时的点患病率戒断率,以及从治疗结束到六个月的持续戒烟率,并通过生化验证(呼出一氧化碳)。我们通过自我报告严重程度来检查尼古丁贴片在缓解特定戒断症状方面的效果。
与安慰剂相比,活性尼古丁贴片在三个月时(48%对21%)和六个月时(33%对14%)的生化确认戒断率显著更高。活性尼古丁组的六个月持续戒烟率(25%)也显著高于安慰剂组(12%)。活性贴片使用者中最常见的不良事件是睡眠障碍和局部皮肤刺激。尼古丁贴片减轻了一些戒断症状的严重程度。低水平的烟瘾是三个月和六个月戒烟的最强预测因素。
经皮尼古丁贴片作为团体认知行为干预的辅助手段是有效的,并且可以缓解与尼古丁依赖相关的戒断症状。